| Formulary Chapter 2: Cardiovascular system - Full Chapter
|
Ticagrelor (Brilique®)
(Tablets)
|
Formulary
|
In combination with aspirin for prevention of atherothrombotic events in ACS - 90mg bd for up to 12 months
In combination with aspirin in people with a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event - 60mg bd for up to 3 years
|
Aspirin (antiplatelet) (Angettes® 75)
|
Non Formulary
|
|
Clopidogrel 300mg (Plavix®)
|
Non Formulary
|
|
Dipyridamole (Persantin®)
|
Non Formulary
|
|
Eptifibatide (Integrilin®)
|
Non Formulary
|
|
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
Primary and Secondary Care (unrestricted) – may be prescribed by GPs, hospital doctors or other qualified prescribers in primary and secondary care |
|
Amber Initiated: first prescription from specialist, on going supplies from primary care (or when stabilised on therapy). |
|
Amber recommended: first prescription may be supplied by primary care under the advice of a specialist. |
|
For initiation within a specialist service followed by ongoing prescribing in primary care according to published shared care guidance |
|
For initiation and ongoing prescribing in secondary care only. Medicines in this category may be further restricted to use by specific hospital departments only. |
|
For prescribing in primary care only |
|
|
Restricted
